Plain-English translation of NCT07188584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new approach to treating advanced nasopharyngeal cancer (a type of throat cancer common in southern China). Patients will receive PD-1 monoclonal antibody immunotherapy along with chemotherapy and radiation. The study compares two radiation strategies: one that targets a smaller area (experimental group) versus the standard approach that targets a larger area (control group). The goal is to see if the reduced-target approach works just as well while potentially reducing side effects.
Advanced nasopharyngeal cancer that has spread to distant parts of the body has historically had very poor survival rates. Recent research showed that combining chemotherapy with radiation significantly improved outcomes, but doctors are now exploring whether focusing the radiation on smaller, high-risk areas — while using this medication to boost the immune system — could be just as effective with fewer complications.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have already completed chemotherapy and immunotherapy before the study begins. You will then be randomly assigned to receive either reduced-target or full-target radiation therapy, along with concurrent cisplatin chemotherapy during radiation and continued immunotherapy (PD-1 monoclonal antibody) for up to 2 years or until your disease progresses. You will need to attend regular clinic visits for imaging scans, blood tests, and treatment monitoring throughout the study period.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China